From the newsletter:
Suboptimal inhaler technique is a major barrier to effectiveness of inhalation therapy. Many patients, particularly the elderly and the very young have difficulty correctly using currently available inhaler devices.
Consequently, there is ongoing research into the development of inhaler devices that are easy to use and provide improved lung deposition. The Respimat® Soft Mist inhaler is a novel, metered-dose device for delivery of inhaled drugs to patients with asthma and chronic obstructive pulmonary disease.
The Respimat® inhaler uses mechanical power from a spring rather than propellants to release a ‘Soft Mist’ which lasts longer and is slower moving than that emitted from a pressurised metered dose inhaler (MDI). As compared to the MDI, which initially releases particles of a relatively large diameter (15 to 20 μm), the Respimat® inhaler releases a high proportion of particles which are respirable (<5μm).
To continue reading the newsletter download it here
A joint initiative of the Patient Services Section and the Drug and Therapeutics Information Service of the Pharmacy Department, Repatriation General Hospital, Daw Park, South Australia. The RGH Pharmacy E-Bulletin is distributed in electronic format on a weekly basis, and aims to present concise, factual information on issues of current interest in therapeutics, drug safety and cost-effective use of medications.
Editor: Assoc. Prof. Chris Alderman, University of South Australia – Director of Pharmacy, RGH © Pharmacy Department, Repatriation General Hospital, Daw Park, South Australia 5041.
If you like this post and what else you see on the blog please subscribe by RSS feed (the orange button) or by email. Visit my subscription page.
{ 2 comments }





